These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36539455)

  • 21. Fast concurrent determination of guaifenesin and pholcodine in formulations and spiked plasma using first derivative synchronous spectrofluorimetric approach.
    Roshdy A; Salam RA; Hadad G; Belal F; Elmansi H
    Luminescence; 2024 Jan; 39(1):e4660. PubMed ID: 38286595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir.
    Ramzy S; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 May; 272():121012. PubMed ID: 35158141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent estimation of some co-administered antimicrobial drugs applying conventional and first derivative synchronous fluorescence spectroscopy techniques.
    El-Aziz HA; Fathy ME; El-Enany N; Aly FA; Tolba MM
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jan; 264():120255. PubMed ID: 34464919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma.
    Megahed SM; Habib AA; Hammad SF; Kamal AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Mar; 249():119241. PubMed ID: 33333412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
    Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
    Elife; 2021 Oct; 10():. PubMed ID: 34617885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synchronous spectrofluorimetric determination of favipiravir and aspirin at the nano-gram scale in spiked human plasma; greenness evaluation.
    Batubara AS; Ainousah BE; Ramzy S; Abdelazim AH; Gamal M; Tony RM
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Oct; 299():122880. PubMed ID: 37216820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma.
    Skaggs C; Zimmerman H; Manicke N; Kirkpatrick L
    J Mass Spectrom Adv Clin Lab; 2022 Aug; 25():27-35. PubMed ID: 35721272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An
    Behera SK; Mahapatra N; Tripathy CS; Pati S
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of Remdesivir in Comparison with Five Approved Antiviral Drugs for Inhibition of RdRp in Combat with SARS-CoV-2.
    Mahdian S; Arab SS
    Iran J Sci Technol Trans A Sci; 2022; 46(5):1359-1367. PubMed ID: 36187298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
    Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
    J A; Francis D; C S S; K G A; C S; Variyar EJ
    J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
    Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
    Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synchronized spectrofluorimetric determination of ponatinib and curcumin as an effective therapeutic combination in laboratory prepared mixtures and human plasma samples.
    El Sharkasy ME; Aboshabana R; Belal F; Walash M; Tolba MM
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jan; 264():120235. PubMed ID: 34371314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
    Schloer S; Brunotte L; Mecate-Zambrano A; Zheng S; Tang J; Ludwig S; Rescher U
    Br J Pharmacol; 2021 Jun; 178(11):2339-2350. PubMed ID: 33825201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2020; 14(4):641-648. PubMed ID: 32428865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
    Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
    Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2.
    Williamson BN; Feldmann F; Schwarz B; Meade-White K; Porter DP; Schulz J; van Doremalen N; Leighton I; Yinda CK; Pérez-Pérez L; Okumura A; Lovaglio J; Hanley PW; Saturday G; Bosio CM; Anzick S; Barbian K; Cihlar T; Martens C; Scott DP; Munster VJ; de Wit E
    Nature; 2020 Sep; 585(7824):273-276. PubMed ID: 32516797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination Treatment With Remdesivir and Ivermectin Exerts Highly Synergistic and Potent Antiviral Activity Against Murine Coronavirus Infection.
    Tan YL; Tan KSW; Chu JJH; Chow VT
    Front Cell Infect Microbiol; 2021; 11():700502. PubMed ID: 34395311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and Validation of High-Performance Liquid Chromatography Method for the Quantification of Remdesivir in Intravenous Dosage Form.
    Jitta SR; Salwa ; Kumar L; Gangurde PK; Verma R
    Assay Drug Dev Technol; 2021; 19(8):475-483. PubMed ID: 34665025
    [No Abstract]   [Full Text] [Related]  

  • 40. Combining subsidiary and synchronous approaches for concurrent spectrofluorimetric assurance of lopinavir and ritonavir in tablets utilized in convention for treatment of coronavirus infection (COVID-19) and biological fluids.
    Salem H; Samir E; Abdelaziz A; Alaa El-Din M; Abdelgaleel M; Zein D; Madian H
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Dec; 262():120066. PubMed ID: 34175754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.